MDGL
Madrigal Pharmaceuticals, Inc.
193.33
-
1.05
0.54%
1 x 193.21
1 x 193.59
bid
ask
1 @ 04:00 PM
193.00-0.33 (0.17%)
Bearish
17
Bullish
21
sentiment
189.00
day range
195.58
120.40
52 week range
312.00
Prev Close194.38
Open192.41
Low189.00
High195.58
Volume453.24K
Avg. Volume594.87K
Market Cap4.05B
Inst. Own94.72%
Beta-0.44
Short Ratio6.17
Div & Yield0.00 /
EPS-19.98
P/E0.00
1yr Target377.07
50day MA242.88
200day MA201.70
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6% | news.google.com • |
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage (NASDAQ:MDGL) | news.google.com • |
Nisa Investment Advisors LLC Sells 90 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) | news.google.com • |
Madrigal Pharmaceuticals (NASDAQ:MDGL) Research Coverage Started at Bank of America | news.google.com • |
Objective long/short (MDGL) Report | news.google.com • |
Madrigal Pharmaceuticals (NASDAQ:MDGL) Receives New Coverage from Analysts at Bank of America | news.google.com • |
Profile
...
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -6.06 | N/A | N/A | N/A |
2024-02-28 | 2023-12 | -5.32 | -5.68 | -0.36 | -6.77% |
2023-11-06 | 2023-09 | -4.78 | -5.34 | -0.56 | -11.72% |
2023-08-08 | 2023-06 | -4.47 | -4.69 | -0.22 | -4.92% |
2023-05-09 | 2023-03 | -4.98 | -4.23 | 0.75 | 15.06% |
2023-02-23 | 2022-12 | -4.41 | -4.98 | -0.57 | -12.93% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-18 | Evercore ISI Group | Upgrade | Outperform | Outperform |
2023-09-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-10 | B. Riley Securities | Upgrade | Neutral | Neutral |
2023-09-04 | B. Riley Securities | Upgrade | Neutral | Neutral |
2023-08-08 | Oppenheimer | Upgrade | Outperform | Outperform |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-01 | BATE KENNETH M | Director | 1.20K | Sale |
2024-04-01 | DALY JAMES M. | Director | 1.20K | Sale |
2024-04-07 | FRIEDMAN PAUL A | Director | 841.28K | Sale |
2024-01-22 | HOWARTH ALEX G | Chief Financial Officer | 18.74K | Stock Award(Grant) |
2024-01-22 | HUNTSMAN CAROLE | Officer | 11.47K | Stock Award(Grant) |
2024-03-31 | LEVY RICHARD S | Director | 10.30K | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baker Brothers Advisors, LLC | 1.55M | 356.92M | 8.36% |
2023-06-29 | Avoro Capital Advisors LLC | 1.52M | 350.00M | 8.20% |
2023-06-29 | Janus Henderson Group PLC | 1.48M | 342.83M | 8.03% |
2023-06-29 | Vanguard Group Inc | 1.47M | 338.54M | 7.93% |
2023-06-29 | Blackrock Inc. | 1.04M | 241.06M | 5.65% |
2023-06-29 | State Street Corporation | 543.76K | 125.61M | 2.94% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 453.15K | 104.68M | 2.45% |
2023-06-29 | Vanguard Small-Cap Index Fund | 377.69K | 87.25M | 2.04% |
2023-06-29 | Janus Henderson Contrarian Fund | 324.94K | 75.06M | 1.76% |
2023-08-30 | iShares Russell 2000 ETF | 310.57K | 55.90M | 1.68% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 263.58K | 47.44M | 1.43% |
2023-06-29 | Vanguard Small Cap Value Index Fund | 261.54K | 60.42M | 1.42% |
Split
...
Split | Date |
---|---|
1 : 35 | 2016-07-25 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6%
news.google.com • -
Objective long/short (MDGL) Report
news.google.com • -
Madrigal Pharmaceuticals Becomes Oversold (MDGL)
news.google.com • -
1 No-Brainer Growth Stock to Buy Now
fool.com • -
The 3 Best Biotech Stocks to Buy in April 2024
investorplace.com • -
2 Top Biotech Buyout Candidates
zacks.com • -
7 Biotech Stocks Ready to Ride the Sector's Resurgence
investorplace.com • -
Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
seekingalpha.com • -
Biotech Stock Soars on FDA Drug Approval
schaeffersresearch.com • -
Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar
proactiveinvestors.com • -
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
investorplace.com • -
Analysts see over 50% gains in these 2 mid-cap biotech stocks
marketbeat.com • -
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
seekingalpha.com • -
Huge Warren Buffett Purchase Highlights Hot Insider Buying
247wallst.com • -
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
investorplace.com • -
2 Risky Stocks With Massive Potential
fool.com • -
Madrigal Pharmaceuticals shares fall after new CEO named
marketwatch.com • -
The 3 Best Biotech Stocks to Buy Now: September 2023
investorplace.com • -
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
investorplace.com • -
The 3 Most Promising Pharma Stocks to Own Now
investorplace.com • -
Madrigal's Resmetirom Nears Commercialization Despite Market Concerns
seekingalpha.com • -
Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next
seekingalpha.com • -
Weight-loss drugs in development aim to replace injections with pills
marketwatch.com • -
Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)
seekingalpha.com • -
Why These 3 Nasdaq Stocks Buckled Today
fool.com • -
3 Biotechs That Might Get Bought Out in 2023
fool.com • -
These Are the Top 10 Holdings of Avoro Capital Advisors
247wallst.com • -
5 Best Stocks to Buy in April
fool.com • -
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
seekingalpha.com • -
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
247wallst.com • -
Madrigal: Fairly Valued At These Levels
seekingalpha.com • -
3 Top Healthcare Stocks to Buy for January
fool.com • -
Why These 7 Healthcare Stocks Could Soar in 2023
investorplace.com • -
Madrigal Pharmaceuticals Setting The Standard
seekingalpha.com • -
Madrigal Pharmaceuticals: Upcoming Windfall Profits
seekingalpha.com • -
7 Drug Stocks That Will Soar in 2023
investorplace.com • -
Madrigal: Next Steps After 'Wow' Data In NASH
seekingalpha.com • -
Madrigal's Successful Late-Stage Trial Draws Options Bulls
schaeffersresearch.com • -
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
marketbeat.com • -
Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today?
investorplace.com • -
Madrigal: Binary Catalyst Unlocking
seekingalpha.com • -
Madrigal Pharmaceuticals Forecast: Not So Clear
seekingalpha.com • -
Madrigal: Buy And Hoard Before Q4 Data Readout
seekingalpha.com • -
Trial Results Set to Make or Break Small-Cap Pharma Stocks
gurufocus.com • -
Madrigal: Clear Path Ahead
seekingalpha.com • -
Madrigal: NASH Data In Q4 Is The Key
seekingalpha.com • -
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
globenewswire.com • -
3 Graham's Lost Formula Stocks to Consider for February
gurufocus.com •